Built from weaker models, sales multiples or analyst targets, so treat it as a rough guide.
Not used by alerts or posts.
Valued as a loss-making company: Sales comps and Analyst consensus.
ACCE opinionTravere Therapeutics Inc. Common Stock (TVTX)
Fair value (2 models)
Not available
ACCE price target
$55.00
Rating
Not rated
Horizon
12 months
ACCE price target published on 11 Oct 2026, 00:00 CEST.
Price used: $50.08 at the close on 23 Oct 2026, 22:00 CEST.
Models: Analyst consensus and Sales comps.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
ACCE score
52
out of 100
Analysts
93% buy
15 covering
P/E
0.0x
forward 39.8x
1-year return
+77.9%
Dividend yield
0.00%
Travere Therapeutics Inc. Common Stock in four questions
Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
Overview
ACCE thesis
Travere Therapeutics sells FILSPARI (sparsentan), an oral dual endothelin and angiotensin receptor antagonist for IgA nephropathy, a chronic kidney disease that progresses toward dialysis in a meaningful share of patients. The product is a specialty kidney franchise with real pricing power and few direct competitors, and the 48.2% revenue growth and 59.2% gross margin show the launch is converting into sales. The near-term question is whether operating margin, currently 2.3%, keeps expanding as revenue scales, since the ROE of -236.4% reflects a balance sheet still carrying losses from the development years. Forward earnings at 39.8 times leave little room for execution slips, so the next few quarters of FILSPARI uptake and the path to sustained profitability will decide whether this name is worth a deeper look.